Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

Rhea-AI Summary

Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, has announced its participation in two upcoming healthcare conferences. The company will engage in analyst-led fireside chats at:

- The 2025 RBC Capital Markets Global Healthcare Conference on May 21st at 8:30 AM ET

- The 2025 Jefferies Global Healthcare Conference on June 4th at 8:45 AM ET

Both events will be accessible via live audio webcast through the "Events" page on Pacira's investor website. Recordings will remain available for two weeks after each event.

News Market Reaction

+4.49%

1 alert

+4.49% News Effect

On the day this news was published, PCRX gained 4.49%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

• 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21^st at 8:30AM ET.
• 2025 Jefferies Global Healthcare Conference on Wednesday, June 4^th at 8:45AM ET.

Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL^® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA^® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº^®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.

Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

FAQ

When is Pacira BioSciences (PCRX) presenting at the RBC Capital Markets Healthcare Conference 2025?

Pacira BioSciences will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st, 2025, at 8:30 AM ET.

How can I access Pacira BioSciences' (PCRX) presentations at the 2025 healthcare conferences?

The presentations can be accessed through live audio webcast on the 'Events' page of Pacira's investor website at investor.pacira.com. Replays will be available for two weeks after each event.

What healthcare conferences is Pacira BioSciences (PCRX) attending in 2025?

Pacira BioSciences is participating in two healthcare conferences: the RBC Capital Markets Global Healthcare Conference on May 21st and the Jefferies Global Healthcare Conference on June 4th, 2025.

When will Pacira BioSciences (PCRX) present at the Jefferies Global Healthcare Conference 2025?

Pacira BioSciences will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4th, 2025, at 8:45 AM ET.